Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 27, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Natural Killer T-cell Lymphoma

Interventions

DRUG

Golidocitinib

150 mg, administered once daily from Day 1 to Day 21 (D1-D21)

DRUG

Benmelstobart

1200 mg, administered on Day 1 (D1) of every cycle

Trial Locations (2)

RECRUITING

Beijing Tongren Hospital, Beijing

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER